Drugs / Interferon γ-1b
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02797080 | Jun 2016 → Mar 2017 | Friedreich ataxia | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT02593773 | Dec 2015 → Mar 2017 | Friedreich ataxia | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT02415127 | Jun 2015 → Nov 2016 | Friedreich ataxia | Amgen | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon γ-1b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02593773 ↗ |
| Route | Subcutaneous | “Subcutaneous (SC) doses of ACTIMMUNE® TIW” NCT02593773 ↗ |